- GlaxoSmithKline (NYSE:GSK) announces a positive outcome from a Phase 3 clinical trial, SYNAPSE, evaluating Nucala (mepolizumab) plus standard-of-care treatment in patients with chronic rhinosinusitis with nasal polyps.
- The study met both co-primary endpoints demonstrating statistically significant improvements in the size of nasal polyps at week 52 and nasal obstruction during weeks 49-52.
- A key secondary endpoint, the time to first actual nasal surgery up to week 52, was also met.
- Regulatory filings are next up.
- Nucala was first approved in the U.S. in November 2015 for asthma.
- Shares down 2% premarket on light volume.